Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

NCT00526474 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

26449

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis
Ischemia
Myocardial Infarction
Cerebrovascular Accident
Peripheral Arterial Disease

Interventions

DRUG: Vorapaxar
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]